A citation-based method for searching scientific literature

Clifford J Bailey. Peptides 2020
Times Cited: 16







List of co-cited articles
112 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
218
68

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
356
43

Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
472
37


GIP and GLP-1, the two incretin hormones: Similarities and differences.
Yutaka Seino, Mitsuo Fukushima, Daisuke Yabe. J Diabetes Investig 2010
331
31

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
370
31

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
87
31

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
25

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism.
Elizabeth A Killion, Michelle Chen, James R Falsey, Glenn Sivits, Todd Hager, Larissa Atangan, Joan Helmering, Jae Lee, Hongyan Li, Bin Wu,[...]. Nat Commun 2020
39
25


Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
341
25

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
96
25

Incretin hormones: Their role in health and disease.
Michael A Nauck, Juris J Meier. Diabetes Obes Metab 2018
272
25

Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions.
Daniela Nasteska, Norio Harada, Kazuyo Suzuki, Shunsuke Yamane, Akihiro Hamasaki, Erina Joo, Kanako Iwasaki, Kimitaka Shibue, Takanari Harada, Nobuya Inagaki. Diabetes 2014
121
25

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.
Jens Juul Holst, Mette Marie Rosenkilde. J Clin Endocrinol Metab 2020
51
25

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
167
25

Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review.
Maria Buur Nordskov Gabe, Wijnand J C van der Velden, Florent Xavier Smit, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde. Peptides 2020
16
18

Inhibition of gastric inhibitory polypeptide signaling prevents obesity.
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
645
18


The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1.
Linda Sundström, Susanna Myhre, Monika Sundqvist, Andrea Ahnmark, William McCoull, Piotr Raubo, Sam D Groombridge, Magnus Polla, Ann-Christin Nyström, Lisbeth Kristensson,[...]. PLoS One 2017
29
18

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Alice E Adriaenssens, Emma K Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y Lam, Ilona Zvetkova, Warren Pan,[...]. Cell Metab 2019
102
18

Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.
A H Sparre-Ulrich, L S Hansen, B Svendsen, M Christensen, F K Knop, B Hartmann, J J Holst, M M Rosenkilde. Br J Pharmacol 2016
59
18

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Lærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, Mette H Jensen, Maria B N Gabe, Alexander H Sparre-Ulrich, Simon Veedfald, Signe Stensen, Amalie R Lanng, Natasha C Bergmann,[...]. Diabetes 2019
78
18


Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study.
Amra Jujić, Naeimeh Atabaki-Pasdar, Peter M Nilsson, Peter Almgren, Liisa Hakaste, Tiinamaija Tuomi, Lisa M Berglund, Paul W Franks, Jens J Holst, Rashmi B Prasad,[...]. Diabetologia 2020
11
27

GLP-1 receptor agonists and cardiovascular outcome trials: An update.
Eirini Andrikou, Costas Tsioufis, Ioannis Andrikou, Ioannis Leontsinis, Dimitrios Tousoulis, Nikolaos Papanas. Hellenic J Cardiol 2019
31
18

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
858
18

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
157
18


Gut hormone polyagonists for the treatment of type 2 diabetes.
Sara J Brandt, Anna Götz, Matthias H Tschöp, Timo D Müller. Peptides 2018
68
18

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Julio Rosenstock, Carol Wysham, Juan P Frías, Shizuka Kaneko, Clare J Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Chrisanthi A Karanikas, Vivian T Thieu. Lancet 2021
134
18

GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review.
Yusaku Mori, Takanori Matsui, Tsutomu Hirano, Sho-Ichi Yamagishi. Int J Mol Sci 2020
16
18

The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation.
Florian Kahles, Ana Liberman, Constantin Halim, Matthias Rau, Julia Möllmann, Robert Werner Mertens, Marcia Rückbeil, Irmgard Diepolder, Benedikt Walla, Sebastian Diebold,[...]. Mol Metab 2018
30
18

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.
M Nagashima, T Watanabe, M Terasaki, M Tomoyasu, K Nohtomi, J Kim-Kaneyama, A Miyazaki, T Hirano. Diabetologia 2011
175
18

Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice.
Yukinori Nogi, Masaharu Nagashima, Michishige Terasaki, Kyoko Nohtomi, Takuya Watanabe, Tsutomu Hirano. PLoS One 2012
53
18

Chylomicrons stimulate incretin secretion in mouse and human cells.
Arianna Psichas, Pierre F Larraufie, Deborah A Goldspink, Fiona M Gribble, Frank Reimann. Diabetologia 2017
37
12

Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut.
Yukihiro Fujita, Ali Asadi, Gary K Yang, Yin Nam Kwok, Timothy J Kieffer. Am J Physiol Gastrointest Liver Physiol 2010
40
12


A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
12

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.
J J Meier, B Gallwitz, N Siepmann, J J Holst, C F Deacon, W E Schmidt, M A Nauck. Diabetologia 2003
227
12

GPR119, a Major Enteroendocrine Sensor of Dietary Triglyceride Metabolites Coacting in Synergy With FFA1 (GPR40).
Jeppe H Ekberg, Maria Hauge, Line V Kristensen, Andreas N Madsen, Maja S Engelstoft, Anna-Sofie Husted, Rasmus Sichlau, Kristoffer L Egerod, Pascal Timshel, Timothy J Kowalski,[...]. Endocrinology 2016
65
12


Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
601
12


A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line.
Fiona M Gribble, Leanne Williams, Anna K Simpson, Frank Reimann. Diabetes 2003
288
12

Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors.
Maria Buur Nordskov Gabe, Alexander Hovard Sparre-Ulrich, Mie Fabricius Pedersen, Lærke Smidt Gasbjerg, Asuka Inoue, Hans Bräuner-Osborne, Bolette Hartmann, Mette Marie Rosenkilde. Biochem Pharmacol 2018
51
12



The role of GIP in α-cells and glucagon secretion.
Kimberley El, Jonathan E Campbell. Peptides 2020
27
12



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.